Onco-receptors targeting in lung cancer via application of surface-modified and hybrid nanoparticles: A cross-disciplinary review

F Sabir, M Qindeel, M Zeeshan, Q Ul Ain, A Rahdar… - Processes, 2021 - mdpi.com
Lung cancer is among the most prevalent and leading causes of death worldwide. The
major reason for high mortality is the late diagnosis of the disease, and in most cases, lung …

Lidocaine inhibits proliferation and metastasis of lung cancer cell via regulation of miR-539/EGFR axis

H Sun, Y Sun - Artificial cells, nanomedicine, and biotechnology, 2019 - Taylor & Francis
Background Despite the medical uses of lidocaine has been well-characterized, the study of
lidocaine's pharmacological function other the anaesthetic effect was never stopped. This …

Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study

JR Yang, JY Xu, GC Chen, N Yu, J Yang, DX Zeng… - Scientific reports, 2019 - nature.com
Non-small cell lung cancer (NSCLC) is the most commonly diagnosed lung cancer and is
associated with poor prognosis. This study aimed to analyze if serum C-reactive protein …

[HTML][HTML] Evaluation of the mutation profile via next-generation sequencing in a Turkish population with non-small cell lung cancer

NK Cetin, İH Erdoğdu, E Bozkurt… - Balkan Medical …, 2021 - ncbi.nlm.nih.gov
Background Lung cancer is the most common cancer type worldwide, with non-small cell
lung cancer being the most frequently studied. Identifying of cancer-related genes in non …

Perbandingan Efikasi Afatinib dan Erlotinib Sebagai Terapi Lini Pertama Kanker Paru Jenis Adenokarsinoma Dengan Mutasi EGFR

BDA Hapsari - 2021 - digilib.uns.ac.id
Metode: Penelitian kohort retrospektif dengan data rekam medis pasien yang terdiagnosis
kanker paru jenis adenokarsinoma dengan mutasi EGFR bulan Januari 2016–31 Desember …

암치료를위한항체치료제에대한고찰: 면역항암제

유한진, 홍세영, 권미지, 이지현, 박희호, 임광석 - KSBB Journal, 2020 - dbpia.co.kr
Recently, biopharmaceutical drugs take a big part in the pharmaceutical market with the
development of genetic engineering. Therapeutic antibodies, one of the representative …